Skip to main content
SpringerLink
Log in

PML risk testing: should Tysabri manufacturers have faith in JC?

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Rudick RA, O'Connor PW, Polman CH, Goodman AD, Ray SS, Griffith NM, Jurgensen SA, Gorelik L, Forrestal F, Sandrock AW, E Goelz S.Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Annals of Neurology: 24 Aug 2010. Available from: URL: http://dx.doi.org/10.1002/ana.22107

  2. Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K, Pace A, Cheung A, Chen LL, Berman M, Zein F, Wilson E, Yednock T, Sandrock A, Goelz SE, Subramanyam M.Anti-JC virus antibodies: Implications for PML Risk Stratification. Annals of Neurology: 24 Aug 2010. Available from: URL: http://dx.doi.org/10.1002/ana.22128

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

PML risk testing: should Tysabri manufacturers have faith in JC?. React. Wkly. 1319, 4 (2010). https://doi.org/10.2165/00128415-201013190-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201013190-00009

Keywords

Search

Navigation